ArticleFrontiers in oncology2025
SMoFFI-SegFormer: a novel approach for ovarian tumor segmentation based on an improved SegFormer architecture.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fluorescence molecular imaging technology: a promising new strategy for the diagnosis and treatment of gynecologic tumors.Frontiers in bioengineering and biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer remains one of the most lethal gynecological malignancies, posing significant challenges for early detection due to its asymptomatic nature in early stages. Accurate segmentation of ovarian tumors from ultrasound images is critical for improving diagnostic accuracy and patient outcomes. In this study, we introduce SMoFFI-SegFormer, an advanced deep learning model specifically designed to enhance multi-scale feature representation and address the complexities of ovarian tumor segmentation. Building upon the SegFormer architecture, SMoFFI-SegFormer incorporates a novel Self-modulate Fusion with Feature Inhibition (SMoFFI) module that promotes cross-scale information exchange and effectively handles spatial heterogeneity within tumors. Through extensive experimentation on two public datasets-OTU_2D and OTU_CEUS-our model demonstrates superior performance with high overall accuracy, mean Intersection over Union (mIoU), and class accuracy. Specifically, SMoFFI-SegFormer achieves state-of-the-art results, significantly outperforming existing models in both segmentation precision and efficiency. This work paves the way for more reliable and automated tools in the diagnosis and management of ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.